Keyphrases
A1 Receptor
100%
Type 2 Diabetes Mellitus (T2DM)
100%
Receptor Agonist
100%
Pharmacokinetics
100%
Glucagon-like
100%
GLP-1 Receptor Agonist
100%
Glucagon-like peptide-1 (GLP-1)
75%
Exendin-4 (Ex-4)
50%
Exenatide Once Weekly
50%
Diabetes
25%
Hemoglobin A1c (HbA1c)
25%
Pancreatitis
25%
Obesity
25%
Literature Search
25%
Tolerability
25%
Mechanism of Action
25%
Cardiovascular Outcome Trials
25%
Safety Data
25%
Efficacy Data
25%
Liraglutide
25%
Safety Concerns
25%
Injection Site Reaction
25%
European Medicines Agency
25%
New Treatment Options
25%
Electronic Literature
25%
Neoplasms
25%
Toxicology
25%
Pharmacokinetic Profile
25%
Short-acting
25%
Pharmacokinetic Parameters
25%
Postprandial Glucose Control
25%
Chemical Structure
25%
Safety Aspects
25%
Assessment Form
25%
United States Food
25%
Legal Documents
25%
Antibody Formation
25%
Tachyphylaxis
25%
Assessment Report
25%
Unique Mechanism
25%
Pharmacology, Toxicology and Pharmaceutical Science
Non Insulin Dependent Diabetes Mellitus
100%
Pharmacokinetics
100%
Glucagon Like Peptide 1 Receptor Agonist
100%
Exendin 4
66%
Glucagon-Like Peptide-1
50%
Hemoglobin A1c
16%
Neoplasm
16%
Tolerability
16%
Liraglutide
16%
Injection Site Reaction
16%
Pharmacokinetic Parameter
16%
Pancreatitis
16%
Tachyphylaxis
16%